Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors from the central anxious procedure, conolidine modulates alternate molecular targets. A Science Innovations study found that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://zionlbkre.canariblogs.com/the-2-minute-rule-for-conolidin-to-replace-traditional-painkillers-53658573